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FGF21 is a biomarker for mitochondrial
translation and mtDNA maintenance
disorders
ABSTRACT
Objective: To validate new mitochondrial myopathy serum biomarkers for diagnostic use.
Methods: We analyzed serum FGF21 (S-FGF21) and GDF15 from patients with (1) mitochondrial
diseases and (2) nonmitochondrial disorders partially overlapping with mitochondrial disorder
phenotypes. We (3) did a meta-analysis of S-FGF21 in mitochondrial disease and (4) analyzed
S-Fgf21 and skeletal muscle Fgf21 expression in 6 mouse models with different muscle-
manifesting mitochondrial dysfunctions.
Results: We report that S-FGF21 consistently increases in primary mitochondrial myopathy,
especially in patients with mitochondrial translation defects or mitochondrial DNA (mtDNA) dele-
tions (675 and 347 pg/mL, respectively; controls: 66 pg/mL, p , 0.0001 for both). This is
corroborated in mice (mtDNA deletions 1,163 vs 379 pg/mL, p , 0.0001). However, patients
and mice with structural respiratory chain subunit or assembly factor defects showed low induc-
tion (human 335 pg/mL, p , 0.05; mice 335 pg/mL, not significant). Overall specificities of
FGF21 and GDF15 to find patients with mitochondrial myopathy were 89.3% vs 86.4%, and
sensitivities 67.3% and 76.0%, respectively. However, GDF15 was increased also in a wide
range of nonmitochondrial conditions.
Conclusions: S-FGF21 is a specific biomarker for muscle-manifesting defects of mitochondrial
translation, including mitochondrial transfer-RNA mutations and primary and secondary mtDNA
deletions, the most common causes of mitochondrial disease. However, normal S-FGF21 does
not exclude structural respiratory chain complex or assembly factor defects, important to
acknowledge in diagnostics.
Classification of evidence: This study provides Class III evidence that elevated S-FGF21 accurately
distinguishes patients with mitochondrial myopathies from patients with other conditions, and
FGF21 and GDF15mitochondrial myopathy from other myopathies. Neurology®2016;87:2290–2299
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; CI 5 confidence interval; CK 5 creatine kinase; FGF21 5 fibroblast growth factor 21;
GDF15 5 growth and differentiation factor 15; mCRC 5 metastasized colorectal cancer; MM 5 mitochondrial myopathy;
mtDNA5mitochondrial DNA; PBC5 primary biliary cirrhosis; PSC5 primary sclerosing cholangitis; RC5 respiratory chain;
S-FGF21 5 serum FGF21; tRNA 5 transfer RNA.
Mitochondrial diseases are the most common form of inherited metabolic disorders. The high
variability in clinical manifestation, heterogeneity of genetic causes with .150 known disease
genes,1 and scarcity of sensitive and specific biomarkers make their diagnosis challenging. Our
original multicenter analysis identified fibroblast growth factor 21 (FGF21) induction in
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genetically confirmed muscle-manifesting
mitochondrial disorders.2 Serum FGF21
(S-FGF21) was both sensitive and specific
for mitochondrial myopathies (MMs), corre-
lating with disease severity and respiratory
chain (RC)-deficient muscle fibers, indicating
high potential for a serum biomarker for mito-
chondrial diseases.2,3 The findings were there-
after replicated in 4 independent cohorts.4–7
Moderately increased S-FGF21 has also been
reported in some nonmitochondrial genetically
heterogeneous disease groups,8–15 leaving the
specificity of FGF21 for MM partially open.
In all reported studies, single patients with
MM showed low FGF21 values, raising the
question of whether the FGF21 response de-
pended on the type of RC deficiency. We
therefore analyzed its induction in different
types of RC dysfunction, and compared the
results to those of a newly suggested mito-
chondrial disease serum biomarker, growth
and differentiation factor 15 (GDF15).6,16–18
We examined S-FGF21 in a variety of non-
mitochondrial disorders with some symptoms
or signs common to mitochondrial diseases.
To deepen understanding of the mechanism
of induction, we analyzed samples from 6
genetically modified mouse models with
mechanistically different RC defects. We pres-
ent here evidence that FGF21 and GDF15
respond especially to MMs caused by mito-
chondrial translation defects or mitochondrial
DNA (mtDNA) deletions, with both similar-
ities and differences in the biomarker response
and specificity.
METHODS Study participants. To study the disease spec-
trum with FGF21 and GDF15 induction, we analyzed previously
collected (years 1993–2013) serum materials from individuals
with a nonmitochondrial disorder/state that shared some pheno-
typic features with mitochondrial disease (muscle/cardiac involve-
ment, late-stage disease, poor prognosis, catabolism, secondary
mitochondrial dysfunction, liver involvement; summarized in
table e-1 at Neurology.org). Details of these populations were
published previously: amyotrophic lateral sclerosis (ALS),e1
cardiomyopathy,e2,e3 lymphoma,e4 metastasized colorectal cancer
(mCRC),e5 nonagenarians,e6 primary biliary cirrhosis (PBC),
primary sclerosing cholangitis (PSC),e7 and statin-induced
myalgia.e8 The genetic background of patients with ALS was as
follows: SOD1 n 5 6; C9ORF72 n 5 1; and unknown n 5 2.
Among cardiomyopathy patients, all had LMNA gene mutations,
normal serum creatine kinase (CK) value, and no signs of skeletal
muscle dysfunction. Statin-induced myalgia samples were drawn
during an acute myalgia period and after clinical recovery. mCRC
samples were drawn before initiation of palliative chemotherapy.
PBC and PSC samples were taken prior to liver transplantation;
clinical data were collected from the latest medical records or the
national liver transplant registry. Fibromyalgia samples were
collected from pain outpatient clinics excluding patients with
a diagnosed muscle disorder and/or severe psychiatric conditions.
Liver function tests were available only from the patients with liver
disease (mCRC, PBC, PSC) and cardiomyopathy.
Figure e-1 summarizes the patient groups and inclusion crite-
ria. Patients with MM included those with meta-analysis of
muscle-manifesting mitochondrial disease2,4,6 and 17 new pa-
tients with a verified genetic diagnosis (table 1 summarizes their
clinical and genetic findings). Serum was collected from 2009 to
2016 and stored at 2808C. Clinical data were collected from the
latest medical records.
Non-MM included 39 patients from previous publications2,4
and 13 new non-MMs (figure e-1 and table 2 summarize clinical
and genetic data). Controls (n 5 87) were from 2 previous pub-
lications,2,6 with no significant difference between S-FGF21 con-
centrations. GDF15 was analyzed from all cohorts, except for
lymphoma or statin myopathy samples (not available).
Mouse models and sampling. Samples were from previously
characterized transgenic mouse models representing mechanisti-
cally different muscle-manifesting RC deficiencies (table 3).
Blood, skeletal muscle, and/or liver samples were collected
immediately after euthanization, snap-frozen in liquid nitrogen,
and stored at 2808C. Serum was separated by letting the blood
clot for 15 minutes at room temperature and centrifuged at
3,000g for 15 minutes at 148C.
Measurement of serum/plasma FGF21 and GDF15 by
ELISA. We measured human serum/plasma FGF21 using 2
ELISA kits (primarily BioVendor, Brno, Czech Republic; results
replicated with R&D Systems, Minneapolis, MN). GDF15 from
human serum/plasma was analyzed with ELISA (R&D Systems).
Mouse samples were measured with a Quantikine Mouse Fgf21
immunoassay (R&D Systems). Absorbance measurements were
performed using a SpectraMax 190 absorbance microtiter plate
reader (Molecular Devices, Sunnyvale, CA).
RNA extraction and analysis of Fgf21 messenger RNA
amount in mice. Fgf21 expression was analyzed using total ex-
tracted tissue RNA and quantitative PCR as previously descri-
bed.e8 Primer sequences and the amplification protocol are
summarized in appendix e-1.
mtDNA deletion analysis in mito-mice. Quantification of
mtDNA heteroplasmy in muscle samples of mito-mice was
done with Southern blot, as previously described.e9 Briefly, XhoI
digested total muscle DNA was separated in 0.6% agarose gel and
transferred to a nylon membrane. Hybridization was performed
with an mtDNA probe, nucleotide positions 1859–2762. Signal
calculation was done with the NIH IMAGE program.
Statistical analysis. Median of S-FGF21 (interquartile range in
parentheses) was used in intergroup comparisons, and 2-tailed
p values ,0.05 were considered significant. For mouse data,
mean and SD were used. Mann–Whitney U test was used to
compare S-FGF21 levels between 2 groups, and Kruskal–Wallis
or 1-way analysis of variance for comparing multiple groups,
followed by the Dunn multiple comparisons test. Comparison
of S-FGF21 and CK values during and after acute statin-induced
myalgia was performed with the Wilcoxon matched-pairs signed
rank test. Spearman rank correlation analysis was used for
associations of S-FGF21 levels to continuous numeric variables.
Nonparametric association was considered significant if r value
was $0.5 and p , 0.05. In case r exceeded 0.5, linear regression
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was performed, and R2 and P (capital p) value for goodness of fit
are shown. To determine sensitivity and specificity, we plotted
the receiver operating characteristic curves and calculated the area
under the curve. Outlier analysis was performed for homogeneous
mouse data, and cleaned data were used for analysis. All statistical
analyses were performed and graphs generated using GraphPad
PRISM 6 (GraphPad Software, La Jolla, CA).
Standard protocol approvals, registrations, and patient
consents. Institutional ethics review boards of all centers
approved the study, participants gave written informed consents,
and the Declaration of Helsinki was followed. Animal procedures
were performed according to protocols approved by the ethical
boards for animal experimentation for each collaborating center.
All experiments were done in accordance with good practice of han-
dling laboratory animals and of genetically modified organisms.
Primary research questions. Are FGF21 and GDF15 induced
in all muscle-manifesting mitochondrial disorders or specific
subgroups? This study demonstrates that S-FGF21 and GDF15
responses are induced in MMs caused by mitochondrial
translation defects and mtDNA deletions, but less in diseases
with RC subunit or assembly mutations. The FGF21 finding is
corroborated in comprehensive mouse model material.
Are FGF21 and GDF15 specific for MM? This study pro-
vides Class III evidence that S-FGF21 distinguishes MM from
other diseases with phenotypic similarities.
RESULTS S-FGF21 and GDF15 are induced in patients
with muscle-manifesting diseases caused by mitochondrial
translation defects or mtDNA deletions. We categorized
patients with MM into 3 groups according to their
genetic defects: (1) directly affecting mitochondrial
translation, (2) primary or secondary mtDNA dele-
tions, and (3) defects affecting RC subunit or assembly
factors (table 1). FGF21 was remarkably elevated in
groups 1 and 2, whereas RC protein structure or
assembly factor mutations elevated S-FGF21 levels on-
ly modestly (figure 1A).
S-FGF21 was significantly higher in children with
mitochondrial translation defects than in adults with
disorders of that group (1,572 pg/mL [1,000–4,179]
and 624 pg/mL [373–983], respectively, p , 0.001)
(figure 1A). S-FGF21 showed no general correlation
to age, as reported previously.3 FGF21 was similarly
induced in patients with sporadic, single, large-scale
mtDNA deletions and or multiple mtDNA deletions,
associated with dominant or recessive disorders of
mtDNA maintenance (531 pg/mL [300–1,231]
and 317 pg/mL [173–1,062], respectively, p5 0.32).
Similar to S-FGF21, GDF15 was increased in
mitochondrial translation and mtDNA deletion dis-
orders, and less in RC complex and assembly defects
(figure 1, A and B). S-FGF21 and GDF15 correlated
significantly among MM groups (figure 1C). Of pri-
mary translation defects, both FGF21 and GDF15
showed the highest induction in patients with differ-
ent mitochondrial transfer RNA (tRNA) mutations
(Leu [UUR], Glu, Ile, Arg). Of mtDNA deletion
disorders, FGF21 was especially increased in Alpers-
Huttenlocher disease and mitochondrial neurogas-
trointestinal encephalomyopathy (secondary multiple
mtDNA deletions caused by POLG1 and TYMPmu-
tations), whereas GDF15 was highest in primary
MMs of adult age, caused by multiple and single
mtDNA deletions. GDF15 showed suggestive posi-
tive correlation, but FGF21 did not, with mutant
mtDNA load in patients with single mtDNA
Table 1 Patients withmitochondrial disease andmuscle manifestation categorized into 3 groups according to
pathogenic mutation
Mutation category Gene Gene name No. Genome
Mitochondrial translation machinery tRNA Transfer RNA 47 mtDNA
rRNA Ribosomal RNA 1 mtDNA
YARS2 Mitochondrial tyrosyl-tRNA synthetase 1 nDNA
MRPL44 Mitochondrial large ribosomal subunit 1 nDNA
mtDNA deletions Twinkle Mitochondrial helicase 5 nDNA
POLG Mitochondrial polymerase gamma 22 nDNA
TYMP Thymidine phosphorylase 10 nDNA
mtDNA Single deletion: tRNAs and RC subunits 8 mtDNA
RC subunits/assembly factors ND1 NADH dehydrogenase subunit 1 2 mtDNA
ND3 NADH dehydrogenase subunit 3 1 mtDNA
ND5 NADH dehydrogenase subunit 5 1 mtDNA
ATP6 ATP synthase 6 1 mtDNA
NDUFS7 NADH dehydrogenase Fe-S protein 7 1 nDNA
SURF1 Surfeit 1 1 nDNA
Abbreviations: mtDNA 5 mitochondrial DNA; NADH 5 nicotinamide adenine dinucleotide; RC 5 mitochondrial respiratory
chain.
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deletions, all of whom had pure MM of similar clin-
ical severity (figure e-2). These findings indicate only
partial overlap in the pathogenic stimuli for the 2
biomarkers.
Nonmitochondrial diseases/traits do not induce S-FGF21
response. In individuals with nonmitochondrial dis-
eases and traits, S-FGF21 never reached 578 pg/mL,
the median in the MM group. Liver-metastasized
colon cancer showed a significant moderate
increase (figure 1D). S-GDF15, analyzed from the
same samples, showed increased concentrations in
most diseases and conditions, except for ALS,
fibromyalgia, and non-MM (figure 1E). The receiver
operating characteristic curves of GDF15 and FGF21
were similar, when MM was compared to differential
diagnostic disease controls (non-MM, ALS) and
healthy participants (figure 1F). However, GDF15
was considerably less sensitive to distinguish MMs
from a wider group of nonmitochondrial severe
disorders (listed in figure 1, D and E) with some
Table 2 Clinical diagnoses, their frequencies, underlying genetic defects, and respective FGF21 and GDF15
values in nonmitochondrial myopathies
Nonmitochondrial myopathies No. Gene (n) Median FGF21, pg/mL Median GDF15, pg/mL
Muscular dystrophies
Duchenne 1 DMD 34 274
Becker 1 DMD 114 1,108
DM1 3 DMPK 24 420
DM2 4 ZNF9 94 304
FSHD 3 Deletion (1) 46 ND
LGMD1B 1 LMNA 98 1,756
LGMD1D 1 DNAJB6 40 ND
LGMD2A 1 CAPN3 81 360
LGMD2I 1 FKRP 63 308
LGMD2L 2 ANO5 162 ND
OPMD 1 PABPN1 251 2,616
Welander 1 TIA1 24 404
Other 1 67
Congenital myopathies
Nemaline myopathy 3 NEB 58 292 (n 5 1)
Other 1 76 ND
Inflammatory myopathies
Necrotizing autoimmune myositis 1 590 ND
IBM 13 193 878 (n 5 6)
IBM-like 1 413 ND
Sarcoid-myopathy sarcoidosis 1 442 ND
Other
Congenital myasthenic syndrome 1 332 ND
Metabolic myopathy 1 209 ND
Myopathy 6 91 ND
Pompe 1 GAA 18 408
Rhabdomyolysis 1 592 ND
SMA2 1 SMN1 436 796
SMA3 1 135 312
Controls ,331a ,1,014a
Abbreviations: DM 5 myotonic dystrophy; FSHD 5 facioscapulohumeral muscular dystrophy; IBM 5 inclusion body myo-
sitis; LGMD 5 limb-girdle muscular dystrophy; ND 5 not determined; OPMD 5 oculopharyngeal muscular dystrophy;
SMA 5 spinal muscular atrophy.
In the gene column, parentheses indicate number of individuals with verified genetic diagnosis.
aNinety-fifth percentile of healthy control values.
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manifestations common to mitochondrial diseases
(figure 1G).
Among conditions typically examined in muscle
clinics (mitochondrial and non-MMs, ALS, and
healthy people who are eventually deemed not to have
a muscle disease), FGF21 sensitivity was 67.3% (95%
confidence interval [CI] 57.8%–75.8%) and specific-
ity 89.3% (95% CI 83.2%–93.8%). GDF15 sensitiv-
ity was 76.0% (95%CI 64.5%–85.4%) and specificity
86.4% (95% CI 77.4%–92.8%). We considered
a value abnormal if the serum concentration exceeded
.331 pg/mL for FGF21 and .1,014 pg/mL for
GDF15 (95th percentile of healthy control values).
Liver is a source of circulating FGF21 during star-
vation19 and hepatic steatosis is reported to induce
FGF21.12,15 We found no correlation of S-FGF21
and liver dysfunction measures (r. 0.5, p, 0.05)
(table e-2). S-FGF21 did not associate with
a-fetoprotein, Ca19-9, and carcinoembryonic anti-
gen in hepatic metastases/cancer predisposing disorders
(mCRC, PBC, and PSC) (data not shown). The
degree of atypia in PSC patient biliary tract brush
cytology samples (1. 5: no atypia. cancer)20 showed
no association with S-FGF21 (data not shown).
To study the prognostic value of S-FGF21 in late-
stage disorders, we correlated S-FGF21 to survival (in
years) in patients who had died within the follow-up
period (n 5 46) and to the MELD (model for end-
stage liver disease) index (in PSC and PBC), but
no association was found (figure e-3, E and F). In
nonagenarians, frailty index, a roughmeasure of mortality
and disability,21 did not mirror S-FGF21 (figure e-3G).
Discontinuation of statin treatment and clinical
remission of myalgia did not alter S-FGF21 in
statin-induced myalgia group (figure e-3, A and B).
However, in cardiomyopathy patients, S-FGF21
showed correlation with plasma B-type natriuretic
peptide (R2 5 0.73, p , 0.0001) and heart ejection
fraction (%) (R2 5 0.56, p , 0.0001) (figure e-3, C
and D), suggesting that decreasing heart dysfunction
can contribute to S-FGF21. However, as a group,
cardiomyopathies did not show significant S-FGF21
increase.
S-Fgf21 is induced in mouse models with muscle-
manifesting RC deficiency caused by mtDNA deletions.
As human patients showed FGF21 induction in spe-
cific mitochondrial disease groups, we analyzed sam-
ples from 6 different congenic mouse models, which
all manifested RC deficiency in the muscle, but had
different types of underlying defect (table 2).
Deletor, K320E-TwinkleMyo mice (secondary multiple
mtDNA deletions), and mito-mice (single mtDNA
deletion) showed a significant induction of S-Fgf21
(figure 2A), whereas Surf1-KO and Ndufs4-KO (RC
complex structural or assembly defects) showed no
increases (figure 2A). Together, the deletion disorders
showed more than 3-fold-higher S-Fgf21 (1,163 pg/
mL [6625]) than controls (379 pg/mL [6233]) or
assembly/structural RC mutations (335 pg/mL
[696]). These results indicated a similar mechanistic
induction of S-Fgf21 in mice as in human patients.
Skeletal muscle is the source of circulating Fgf21 in MM
mice. To investigate the role of skeletal muscle as the
















Mild MM and cardiac hypertrophy Multiple large mtDNA deletions, 5%–
15% of muscle fibers COX-negative




















mtDNA deletion; combined RC
deficiency; 20%–60% no apparent
manifestation




Surf1-KO Surfeit gene 1 Mild mitochondrial myopathy,
mildly decreased motor skills
COX-negative muscle fibers, 30%–
40% residual COX activity




Small size, progressive ataxia Severe complex I deficiency
(systemic)







Early graying, low body weight,
liver abnormalities, late renal
phenotype, and moderately
shortened lifespan
mtDNA depletion (25% of normal),
5%–6% of muscle fibers COX-
negative
21 mo 3–5 mo (6 mo) 38
Abbreviations: COX 5 cytochrome c oxidase; KO 5 knockout; MM 5 mitochondrial myopathy; mtDNA 5 mitochondrial DNA; NADH 5 nicotinamide adenine
dinucleotide; RC 5 mitochondrial respiratory chain; tRNA 5 transfer RNA.
aMito-mice show the onset of mitochondrial diseases when the proportion of ΔmtDNA reaches 70%–80% in affected tissues. In the severe case, mito-
mice begin to die at around 6 months of age of renal failure.
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Figure 1 S-FGF21 is increased in MMs caused by defective mitochondrial translation or mtDNA deletions
(A) Median (IQR) of S-FGF21 in different MM groups: Mt translation 675 pg/mL (437–1,504), mtDNA deletions 347 pg/mL (206–1,062), RC structure and
assembly 335 pg/mL (54–604), and controls 66 pg/mL (48–104). (B) Median S-GDF15 (IQR) in different MM groups: Mt translation 3,092 pg/mL (1,844–
4,868), mtDNA deletions 1,520 pg/mL (852–3,403), RC structure and assembly 512 pg/mL (348–1,178), and controls 328 pg/mL (235–474). (C) Corre-
lation between S-FGF21 and GDF15 in MMs. Blue and red dots indicate patients considered outliers and were not included in the linear regression. Blue
patient: mtATP6 mutation; red patient: tRNALeu-UUR. (D) Median (IQR) of S-FGF21 for the nonmitochondrial diseases and traits, MM, and controls: ALS 98 pg/
mL (62–196), cardiomyopathy 47 pg/mL (45–223), fibromyalgia 45 pg/mL (39–135), lymphoma 39 pg/mL (38–162), mCRC 170 pg/mL (75–566),
nonagenarians 181 pg/mL (45–325), PBC 121 pg/mL (62–466), PSC 84 pg/mL (42–157), SM acute phase 4 pg/mL (1–241), SM post acute phase 90 pg/mL
(1–269), non-MM 101 pg/mL (46–309), MM 576 pg/mL (289–1,187), and controls 66 pg/mL (48–104). (E) Median (IQR) of S-GDF15 for the nonmitochon-
drial diseases and traits, MM, and controls: ALS 760 pg/mL (582–1,284), cardiomyopathy 558 pg/mL (456–993), fibromyalgia 407 pg/mL (359–518),
mCRC 2,082 pg/mL (1,332–2,625), nonagenarians 2,007 pg/mL (1,397–3,489), PBC 3,706 pg/mL (2,706–6,794), PSC 2,026 pg/mL (774–4,371), non-
MM 796 pg/mL (344–1,056), MM 2,146 pg/mL (1,024–4,312), and controls 328 pg/mL (235–474). (F) ROC curves for FGF21 and GDF15: MM patients
compared to nonmitochondrial muscle diseases and controls. AUC for FGF21 is 0.88 (95%CI 0.84–0.93) and for GDF150.89 (95%CI 0.84–0.94). (G) ROC
Continued
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source of circulating Fgf21 in MM, we analyzed mus-
cle Fgf21messenger RNA levels in all 6 mouse models
and their controls (figure 2B). Consistent with serum
results (figure 2A), we found a strong induction of
Fgf21 expression in Deletor mice and a milder induc-
tion in K320E-TwinkleMyo mice compared to con-
trols. In mito-mice, the expression of Fgf21 in the
skeletal muscle trended upward. No Fgf21
expression was detected in the muscle of Surf1-KO,
Ndufs4-KO, or Mpv17-KO mice, consistent with
their low S-Fgf21. In mito-mice with a single
mtDNA deletion, heteroplasmy level of mutant
mtDNA associated significantly (r . 0.5, p ,
0.05) with both S-Fgf21 level (R2 5 0.48, p ,
0.05) and muscle Fgf21 expression (R2 5 0.41, not
significant) (figure 2, C and D). In addition, we
correlated S-FGF21 values with corresponding
muscle expression of Fgf21 in mice and detected
a significant correlation (R2 5 0.43, p , 0.001)
(figure 2E). Since liver is another known source of
circulating Fgf21, we analyzed liver expression of
Fgf21 in Deletor, Surf1, and Mpv17 mice, which
showed no induction compared to controls (data
not shown).
Together, these data from human and mice indi-
cate that FGF21 expression responds to defects with
single large-scale/multiple mtDNA deletions or
impaired mitochondrial translation machinery, and
that the likely source of S-FGF21 is the skeletal
muscle.
DISCUSSION Our results define S-FGF21 as a spe-
cific tool in mitochondrial disease diagnostics, espe-
cially raised in MMs with affected mitochondrial
translation—the most common cause of MM—but
not in structural RC complex or assembly deficiencies.
The newly reported GDF15 identifiedMMs well from
non-MMs, with higher sensitivity and lower
specificity, but was also induced in a wide variety of
different kinds of severe diseases of nonmitochondrial
origin. These data support the value of both FGF21
and GDF15 in first-line diagnosis of muscle disorders.
The usefulness of FGF21 as a serum marker for
mitochondrial disease has been validated in 4 stud-
ies.2–7 However, single MM outliers without induc-
tion led us to ask whether the mechanism of response
was related to specific kinds of dysfunction. Our
patient and mouse data, supplemented by literature
review, pointed to the highest induction of FGF21
response in disorders that primarily or secondarily
affect mitochondrial translation—direct mutations
of translation machinery or mtDNA deletions leading
to imbalance of mtDNA-encoded tRNAs and rRNAs
—but not mutations in structural RC complexes or
their assembly factors. mtDNA maintenance disor-
ders, such as those caused by nuclear gene mutations
in POLG, C10orf2, or TYMP, also cause mtDNA
deletions or point mutations,22–24 and induced
FGF21. Consistent with human data, mouse models
accumulating multiple mtDNA deletions in skeletal
muscle,25,26 or mice with a single large heteroplasmic
mtDNA deletion,27 induced Fgf21, clearly linking
mtDNA deletions to the cytokine response. Mpv17
KO mice did not elicit Fgf21 response, which may be
linked with mtDNA depletion or the unknown
Mpv17 function. Recently, heart- and muscle-
specific DARS2-KO (mitochondrial aspartyl-tRNA
synthetase) mice, with impaired mitochondrial trans-
lation machinery and mosaic RC deficiency, were
reported to show a robust increase of Fgf21 in their
heart.28 These data strongly support the conclusion
that impaired mitochondrial translation is a primary
trigger for FGF21 response.
FGF21 concentration has been suggested to reflect
the severity of disease.2,7 Previously, S-FGF213 or
FGF21 messenger RNA2 were found to correlate to
the amount of RC-deficient muscle fibers in human
patients and Deletor mice. Here, we show mutant
mtDNA amount correlating with S-Fgf21 and muscle
Fgf21-RNA in mito-mice, and S-FGF21 in patients
with single mtDNA deletions. These data suggest that
FGF21 reflects muscle disease severity, indicating
potential for follow-up of MM progression.
High S-FGF21 values were reported in patients
with end-stage mitochondrial disease,2 suggesting
that FGF21 could be induced by tissue degeneration
or multiple organ failure. Furthermore, GDF15 con-
centrations were high in a variety of severe disorders,
including pulmonary hypertension and end-stage
heart failure.29,30 We found that S-FGF21 correlated
with prohormone brain natriuretic peptide and ejec-
tion fraction %, suggesting that heart failure could
induce FGF21. Despite reports of increased expres-
sion of FGF21 in the liver in hepatic stress and hep-
atocarcinogenesis in mice and humans,31 we found no
S-FGF21 increase in liver pathology (mCRC, PBC,
PSC), nor did it associate with liver dysfunction tests
or degree of atypia in biliary tracts, indicating that
FGF21 is not a general consequence of liver disease.
Poor disease prognosis or general frailty did not
Figure 1 legend, continued:
curves with MM against non-MM, other diseases and traits, and controls. AUC for FGF21 is 0.86 (95% CI 0.81–0.90) and for GDF15 0.70 (95% CI 0.64–
0.76). Note the discontinuous y-axes in A–E. Number of participants is in parentheses. Statistical significance: *p , 0.05, ****p , 0.0001. ALS 5
amyotrophic lateral sclerosis; AUC 5 area under the curve; CI 5 confidence interval; IQR 5 interquartile range; mCRC 5 metastasized colorectal cancer;
MM 5 mitochondrial myopathy; Mt 5 mitochondrial; mtDNA 5 mitochondrial DNA; PBC 5 primary biliary cirrhosis; PSC 5 primary sclerosing cholangitis;
RC 5 mitochondrial respiratory chain; ROC 5 receiver operating characteristic; SM 5 statin-induced myalgia.
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stimulate S-FGF21. All these conditions did increase
GDF15, even to similar levels as in MM. However,
within the group of muscle disorders, including ALS
and inclusion body myositis with secondary mitochon-
drial abnormalities, both GDF15 and FGF21 sensi-
tively identified primary MM patients, suggesting
Figure 2 MM in mice induces secretion of Fgf21 by skeletal muscle
(A) Mean (6SD) S-Fgf21 levels in mouse models: Deletor 1,460 pg/mL (6679), K320E-TwinkleMyo 911 pg/mL (6236), mito-mice 778 pg/mL (6454), Surf1-
KO 382 pg/mL (69), Ndufs4-KO 264 pg/mL (6141), and controls 379 pg/mL (6233). (B) Skeletal muscle (QF) expression of Fgf21 gene normalized to
b-actin in MM mouse models. AU mean expression (6SD) compared to controls normalized as 1 (60.71): Deletor 21.4X (611), K320E-TwinkleMyo 9.23X
(63.28), mito-mice 4.90X (63.47), Surf1-KO 1.15X (60.37), Mpv17-KO 0.58X (60.59), and Ndufs4-KO 1.13X (60.35). (C) Association of S-Fgf21 with
mtDNA deletion load in muscle of mito-mice. (D) Association of QF expression of Fgf21 with mtDNA deletion load in muscle of mito-mice. (E) S-Fgf21
association with corresponding QF expression of the Fgf21 gene in all mouse models. Number of mice is in parentheses. *p , 0.05, **p , 0.01, ****p ,
0.0001. AU5 artificial unit; MM5mitochondrial myopathy; mtDNA5mitochondrial DNA; ns5 not significant; QF5 quadriceps femoris; RC5mitochondrial
respiratory chain.
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that both biomarkers could be useful in serum-
diagnostic work of patients in a muscle clinic.
To elucidate the role of secondary muscle mito-
chondrial pathology in FGF21 induction, we studied
patients with statin-induced myalgia as well as
elderly patients. Statins are inhibitors of HMG-CoA
(3-hydroxy-3-methyl-glutaryl-coenzyme A) reduc-
tase, which participates in mitochondrial ubiquinone
synthesis.32 The mechanisms of statin myopathy are
complex, also involving mitochondrial RC complex
III deficiency by direct binding of the drug to the
enzyme.33 S-FGF21 did not respond to statin-
induced muscle events, even in the acute phase. Fur-
thermore, despite low amounts of mtDNA deletions
in skeletal muscle of normal aging individuals,34
S-FGF21 was not increased even in people in their
10th decade. However, single individuals with non-
mitochondrial diseases showed high S-FGF21 values
and without a genetic diagnosis, the possibility of an
undiagnosed mitochondrial disease remains. Overall,
the findings support the specificity of FGF21 induc-
tion in primary mitochondrial disease.
Our study corroborates the role of S-FGF21 as
a valuable biomarker for MMs. Increased values in
patients’ sera point to defects in mitochondrial trans-
lation machinery or mtDNA maintenance, the most
common causes of mitochondrial disease. We pro-
pose this biomarker for first-line diagnosis of muscle
clinic patients. However, in clinical manifestations
consistent with Leigh syndrome or Leber hereditary
optic atrophy, typically associated with structural or
assembly defects of RC complexes, S-FGF21 can
remain low. Our evidence indicates that GDF15
has a related mechanism of induction in skeletal mus-
cle as FGF21, but is also increased in a spectrum of
nonmitochondrial pathologic conditions and upon
high age. Both biomarkers outperform the sensitivity
of conventional biomarkers CK and lactate,3,35 but
induction of GDF15 in many severe nonmitochon-
drial disorders is important to acknowledge and may
limit its use in diagnostics in relation to FGF21. Of
note, our data show that the physiologic consequen-
ces of RC deficiency in skeletal muscle are dictated by
the primary molecular disease mechanism, and not by
its downstream endpoint, RC deficiency.
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